Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study.
Mihatov, Nino, Eric A Secemsky, Dean J Kereiakes, Gabriel Steg, Donald E Cutlip, Ajay J Kirtane, Roxana Mehran, et al. 2022. “Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study.”. Cardiovascular Revascularization Medicine : Including Molecular Interventions 41: 105-12.